C3N-02089
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 76.41341547
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.560
- E2F_TARGETS+0.440
- OXIDATIVE_PHOSPHORYLATION+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- G2M_CHECKPOINT+0.360
- PANCREAS_BETA_CELLS+0.360
- SPERMATOGENESIS+0.340
- MTORC1_SIGNALING+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- INTERFERON_ALPHA_RESPONSE-0.440
- UV_RESPONSE_DN-0.390
- NOTCH_SIGNALING-0.370
- APICAL_JUNCTION-0.350
- HEDGEHOG_SIGNALING-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- MYOGENESIS-0.340
- TGF_BETA_SIGNALING-0.300
- APOPTOSIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8392889 | — | cohortMD1 | 0.876 |
| 2 | SRR8518298 | — | E | 0.859 |
| 3 | 20090275.TNBC | — | E | 0.859 |
| 4 | TCGA-YC-A9TC-01A-22R-A39I-07 | — | — | 0.859 |
| 5 | TCGA-AN-A04C-01A-21R-A034-07 | — | C | 0.854 |
| 6 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.853 |
| 7 | SRR8518376 | — | E | 0.852 |
| 8 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.852 |
| 9 | TCGA-86-A4D0-01A-11R-A24H-07 | — | cohortA3 | 0.846 |
| 10 | TCGA-22-4613-01A-01R-1443-07 | — | cohortSQ2 | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |